VACCINE INNOVATION

VBI Vaccines is developing safe and effective vaccines that seek to
expand vaccine protection in both established and emerging markets

About VBI    CMV Vaccine

About VBI Vaccines

VBI Vaccines, Inc. (Nasdaq: VBIV) is a biopharmaceutical company developing novel technologies that seek to expand vaccine protection in large underserved markets. VBI’s eVLP vaccine platform allows for the design of enveloped (“e”) virus-like particle (“VLP”) vaccines that closely mimic the target virus. The company’s lead eVLP asset is a prophylactic Cytomegalovirus (CMV) vaccine; VBI has initiated work for GMP manufacturing of its CMV candidate for use in formal preclinical and Phase I trials. The company’s second platform is a thermostable technology that enables the development of vaccines and biologics that can withstand storage or shipment at constantly fluctuating temperatures. VBI has completed proof of concept thermostability studies on a number of vaccine and biologic targets. VBI is headquartered in Cambridge, MA with research facilities in Ottawa, Canada.

eVLP PLATFORM

VBI’s eVLP vaccine technology allows for the design of enveloped (“e”) Virus Like Particle (“VLP”) vaccines that more closely mimic the structure of enveloped viruses than currently marketed VLP vaccines. VLPs are designed to resemble the structure of viruses, but do not contain any potentially infectious viral material.

Learn More

CMV VACCINE CANDIDATE

VBI is developing a prophylactic eVLP-based vaccine to prevent CMV infection and disease with a Phase I trial anticipated beginning in 2015. Approximately 5,000 U.S. infants will develop permanent problems due to CMV each year, some of them severe, including deafness, blindness, and mental retardation.

Learn More

THERMOSTABLE PLATFORM

As an alternative to reliance on the cold chain, VBI’s LPV™ technology enables thermostable vaccine delivery, which is expected to increase vaccine safety, efficacy, and access in both established and emerging markets. VBI has completed proof of concept studies on a number of vaccine and biologic targets.

Learn More